229 related articles for article (PubMed ID: 33167712)
1. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
[TBL] [Abstract][Full Text] [Related]
2. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
3. [DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients].
Chu X; Zhao W; Wang B
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Apr; 35(4):357-361. PubMed ID: 31167696
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
Schotten LM; Darwiche K; Seweryn M; Yildiz V; Kneuertz PJ; Eberhardt WEE; Eisenmann S; Welter S; Sisson BE; Pietrzak M; Wiesweg M; Ploenes T; Hager T; He K; Freitag L; Aigner C; Taube C; Oezkan F
Eur J Cancer; 2021 Apr; 147():142-150. PubMed ID: 33662689
[TBL] [Abstract][Full Text] [Related]
5. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
6. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders.
Konecny M; Markus J; Waczulikova I; Dolesova L; Kozlova R; Repiska V; Novosadova H; Majer I
Neoplasma; 2016; 63(2):246-53. PubMed ID: 26774146
[TBL] [Abstract][Full Text] [Related]
7. Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.
Zang R; Wang X; Jin R; Lei Y; Huang J; Liu C; Zheng S; Zhou F; Wu Q; Sun N; Gao S; He J
J Transl Med; 2019 Dec; 17(1):430. PubMed ID: 31888670
[TBL] [Abstract][Full Text] [Related]
8. miR-375 Combined with SHOX2 Methylation has Higher Diagnostic Efficacy for Non-Small-Cell Lung Cancer.
Zeng S; Lin C; Huang Y
Mol Biotechnol; 2023 Jul; 65(7):1187-1197. PubMed ID: 36462101
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic Efficacy of SHOX2 Gene Hypermethylation for Lung Cancer: A Meta-Analysis].
Liu Q; Wang S; Pei G; Yang Y; Huang Y
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):490-496. PubMed ID: 34275516
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of lung malignant epithelial cells by gene methylation analysis in the conditionally reprogrammed cell cultures.
Wu GD; Xiao YG; Fang FY; Yao D; Liu J; Cao YH; Mao Y; Yu B; Yao TR; Wu YM; Qian YH; Yu DH
Neoplasma; 2020 May; 67(3):692-699. PubMed ID: 32202907
[TBL] [Abstract][Full Text] [Related]
12. The performance of the
Xu Z; Wang Y; Wang L; Xiong J; Wang H; Cui F; Peng H
Biomark Med; 2020 Apr; 14(5):341-351. PubMed ID: 32250153
[No Abstract] [Full Text] [Related]
13. Promoter hypermethylation of
Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
[TBL] [Abstract][Full Text] [Related]
14. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
[TBL] [Abstract][Full Text] [Related]
15. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
17. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging.
Darwiche K; Zarogoulidis P; Baehner K; Welter S; Tetzner R; Wohlschlaeger J; Theegarten D; Nakajima T; Freitag L
Ann Oncol; 2013 Nov; 24(11):2866-70. PubMed ID: 24026539
[TBL] [Abstract][Full Text] [Related]
18. A novel multimodal prediction model based on DNA methylation biomarkers and low-dose computed tomography images for identifying early-stage lung cancer.
Zhang J; Yao H; Lai C; Sun X; Yang X; Li S; Guo Y; Luo J; Wen Z; Tang K
Chin J Cancer Res; 2023 Oct; 35(5):511-525. PubMed ID: 37969955
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.
Zhou X; Lu X; Wu H; Liu J; Huang H
Thorac Cancer; 2021 Dec; 12(24):3327-3332. PubMed ID: 34741433
[TBL] [Abstract][Full Text] [Related]
20. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis.
Ilse P; Biesterfeld S; Pomjanski N; Wrobel C; Schramm M
Cancer Genomics Proteomics; 2014; 11(5):251-8. PubMed ID: 25331797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
